4. 5) forventes det, at plasmakoncentrationen af nelfinavir øges, mens koncentrationen af tert- butyl hydroxynelfinavir vil være ubetydelig eller ikke- målelig.
It is expected that in CYP2C19 poor metabolisers or in patients receiving concomitantly strong CYP2C19 inhibitors (see section 4.5), nelfinavir plasma levels would be elevated whereas levels of tert-butyl hydroxy nelfinavir would be negligible or non-measurable.